Zobrazeno 1 - 10
of 21
pro vyhledávání: '"William H. Isacoff"'
Publikováno v:
Cancers; Volume 14; Issue 12; Pages: 2906
Cytotoxic chemotherapy remains the mainstay of treatment for advanced pancreatic adenocarcinoma (PDAC). Emerging studies support metronomic chemotherapy (MCT) as effective, challenging established paradigms of dosing and schedules. The blood-based Ch
Pharmacogenomic blood-based assay to predict chemotherapy response and survival in pancreatic cancer
Autor:
Kenneth H. Yu, Fay M. Purcell, Brian C. McCarthy, Eileen M. O'Reilly, Devan McCarthy, Jennifer Park, William H. Isacoff, Brandon Cooper, Andrew Bartlett
Publikováno v:
Journal of Clinical Oncology. 38:738-738
738 Background: Pancreatic adenocarcinoma (PDAC) is for most patients a refractory disease. Modern cytotoxic chemotherapeutics (C) are not yet optimal for inducing responses and extending life. We are developing a blood-based pharmacogenomic (PGx) as
Autor:
William Arthur Hoos, Lola Rahib, Timothy R. Donahue, O. Joe Hines, Alexander Upfill-Brown, Rudolph A. Bedford, Howard A. Reber, William H. Isacoff
Publikováno v:
Targeted oncology, vol 13, iss 4
Targeted Oncology
Targeted Oncology
BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer. As a protracted low-dose infusion, 5FU is antiangiogenic, and has synergy w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6245bfdfbfa54e0425ad4e7f95243957
https://escholarship.org/uc/item/8725b6g9
https://escholarship.org/uc/item/8725b6g9
Autor:
James S. Tomlinson, Zev A. Wainberg, O. Joe Hines, Timothy R. Donahue, Jacob S. Ankeny, Matthew M. Rochefort, William H. Isacoff, Brian E. Kadera, Howard A. Reber, Graham W. Donald
Publikováno v:
Rochefort, MM; Ankeny, JS; Kadera, BE; Donald, GW; Isacoff, W; Wainberg, ZA; et al.(2013). Impact of Tumor Grade on Pancreatic Cancer Prognosis: Validation of a Novel TNMG Staging System. ANNALS OF SURGICAL ONCOLOGY, 20(13), 4322-4329. doi: 10.1245/s10434-013-3159-3. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3xw82449
Annals of surgical oncology, vol 20, iss 13
Annals of surgical oncology, vol 20, iss 13
BackgroundPancreatic ductal adenocarcinoma (PDAC) patients demonstrate highly variable survival within each stage of the American Joint Committee on Cancer (AJCC) staging system. We hypothesize that tumor grade is partly responsible for this variatio
Publikováno v:
Journal of Gastrointestinal Surgery
Donahue, Timothy R.; Kazanjian, Kevork K.; Isacoff, William H.; Reber, Howard A.; & Hines, O. Joe. (2010). Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 14(6), pp 1012-1018. doi: 10.1007/s11605-010-1187-x. Retrieved from: http://www.escholarship.org/uc/item/6gf7s3cc
Donahue, Timothy R.; Kazanjian, Kevork K.; Isacoff, William H.; Reber, Howard A.; & Hines, O. Joe. (2010). Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 14(6), pp 1012-1018. doi: 10.1007/s11605-010-1187-x. Retrieved from: http://www.escholarship.org/uc/item/6gf7s3cc
Background Patients with unresectable pancreatic cancer (PDAC) or endocrine tumors (PET) often develop splenic vein thrombosis, hypersplenism, and thrombocytopenia which limits the administration of chemotherapy. Methods From 2001 to 2009, 15 patient
Autor:
David A. Dezentje, Michael J. Swartz, Michiel S. van der Heijden, Angelo M. DeMarzo, G. Johan A. Offerhaus, Jonathan R. Brody, Scott E. Kern, William H. Isacoff, Steven C. Cunningham, Eike Gallmeier, Ralph H. Hruban
Publikováno v:
Clinical cancer research, 11(20), 7508-7515. American Association for Cancer Research Inc.
Purpose: BRCA2, FANCC, and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to interstrand cross-linkers in vivo and a more optimal treatment of pancreatic cancer patients based
Autor:
Allyson J. Ocean, William H. Isacoff, Kenneth H. Yu, Mark Ricigliano, Mary Welkie, Andrew Bartlett, Brandon Cooper
Publikováno v:
Journal of Clinical Oncology. 35:338-338
338 Background: Standard of care treatment for pancreatic adenocarcinoma (PDAC) includes FOLFIRINOX or gemcitabine with nab-paclitaxel used in either the front-line or 2nd line treatment setting. There is no consensus for 3rd line treatment for this
Publikováno v:
The American Surgeon. 66:827-831
The accuracy of endoscopic ultrasound (EUS) for initial staging of esophageal cancer is widely accepted. There is, however, considerable variability in the reported accuracy of EUS for restaging of esophageal neoplasms after neoadjuvant therapy. From
Autor:
William H. Isacoff, Philip A. Philip
Publikováno v:
Journal of Clinical Oncology. 26:162-164
Autor:
William H. Isacoff, Katrina Borud
Publikováno v:
World Journal of Surgery. 21:748-762
Approximately 50% of patients with colorectal cancer develop locally recurrent or distant metastatic disease during the course of their illness and eventually die. Since the 1950s the mainstay of treatment for patients in need of palliative therapy h